$NRBO

NeuroBo Pharmaceuticals Inc

  • NASDAQ
  • Health Technology
  • Pharmaceuticals: Major
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$0.471 -

Delayed Price

VOLUME

13,897

DAY RANGE

-

52 WEEK

0.3732 - 5.63

Join Discuss about NRBO with like-minded investors

profile
@nepestheone #StockTraders.NET
recently

1/4/2022 [9:04 AM] GNPX- will ssr around low 3s so watching pops to 3.50-3.80 for a trade back to 3 or below [9:04 AM] PSTV- ideally gets loco and we see 2.50-3+ im not interested til those levels [9:05 AM] RELI- watching retest if 7.50-8.50 for short back sub 7 i will ignore if it drops sub 7 [9:05 AM] IMMX- no interest [9:06 AM] NRBO- reshort using 2.30-2.50 retest [9:09 AM] ISPC- possible short using 10.50-11.50 res gauge for a scalp

96 Replies 9 👍 12 🔥

profile
@Math #StockTraders.NET
recently

$WTRH $CEI $PROG $BMRA $BBIG $NRBO $PLUG $KOSS $OCGN

82 Replies 9 👍 10 🔥

profile
@Chano #StockTraders.NET
recently

$NRBO was a 20x float rotation, this one so far is 3x and biggest volume has passed, I calculate around 8x for the rest of the day, let's see

47 Replies 8 👍 9 🔥

profile
@maletone #StockTraders.NET
recently

could pull a $NRBO like move from yesterday

83 Replies 12 👍 10 🔥

SO
@soheil.n #StockTraders.NET
recently

watchlist: $AEHR, $NRBO, $MRNA - all 2nd red day potential (pending borrows)....$CYTK looking for rejection around 29.5-30

135 Replies 13 👍 13 🔥

profile
@maletone #StockTraders.NET
recently

took some $NRBo long

134 Replies 13 👍 11 🔥

SO
@soheil.n #StockTraders.NET
recently

quick #firstbounce on $NRBO ...went long 4.88 and sold before 5

64 Replies 15 👍 9 🔥

profile
@Neptune5045 #StockTraders.NET
recently

$nrbo and $nuro stuffed at the same time

130 Replies 13 👍 13 🔥

SO
@soheil.n #StockTraders.NET
recently

so #firstbounce in play for $NRBO at 4.9s and $NURO at these levels (pending the flush: $8s and 7.4s

134 Replies 12 👍 11 🔥

SO
@soheil.n #StockTraders.NET
recently

and $NRBO - but not borrows for both :(

62 Replies 9 👍 9 🔥

SO
@soheil.n #StockTraders.NET
recently

$NRBO ripping....was planning to long at 4.2 but MRNA took over attention

53 Replies 13 👍 6 🔥

SO
@soheil.n #StockTraders.NET
recently

$NRBO push caught me off gaurd

118 Replies 12 👍 14 🔥

SO
@soheil.n #StockTraders.NET
recently

watchlist: $AEHR (pending borrows)...$NRBO (blvd at 4.86 - area of interest would be 4.8-5 for rejection)...$MRNA may buy the dip for a possible para

54 Replies 12 👍 7 🔥

Key Metrics

Market Cap

12.56 M

Beta

0

Avg. Volume

57.64 K

Shares Outstanding

26.66 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-15

Next Dividend Date

Company Information

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of 4 drug candidates. The company's recently acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. ANA001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Due to global COVID-19 crisis, a planned Phase 3 study was postponed. In the interim, NeuroBo is exploring a potential orphan drug indication targeting chronic pain for NB-01. NeuroBo's NB-02 drug candidate is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. The company's fourth program, Gemcabene, was developed for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease.

Website:

HQ: ,

Related News